Skip to content

The health benefits of continue ingested test food (HBF2018-01): a randomized double-blind, paralled-group, placebo-controlled study

The health benefits of continue ingested test food (HBF2018-01): a randomized double-blind, paralled-group, placebo-controlled study - The health benefits of test food (HBF2018-01)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000033536
Enrollment
50
Registered
2018-09-07
Start date
2018-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanease adults

Interventions

Oral ingestion of the test food(HBF2018-01) twice a day(at lunch time and at dinner time) for 12 weeks Oral ingestion of the placebo control food twice a day(at lunch time and at dinner time) for 12 w

Sponsors

Hayashibara CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Healthy Japanease adults 2)Employees at the Hayashibara CO.,LTD. 3)Subjects who signed the informed consent for participation in the study 4)Individuals judged appropriate for the study by the principal investigator

Exclusion criteria

Exclusion criteria: 1)Subjects with medical fistory of sever disorders 2)Pregnant or have possibility to become pregnant during the study or lactating women 3)Subjects who judged as unsuitable for this study by the principal investigator for any reasons 4)Subjects who are being treated with hyperglycemia. 5)Subjects who have been diagnosed with diabetes in the past 6)Subjects who can not comply with the instruction of conducting the test

Design outcomes

Primary

MeasureTime frame
1.Blood glucose, insulin Measuring: at 0 and 12 weeks after ingestion

Secondary

MeasureTime frame
1.Body physical measurement 2.Blood biochemical examination 3.Blood pressure 4.PAI-1 ,HMW-adiponectctin 2,4 Measuring: at 0 and 12 weeks after ingestion 1,3 Measuring:at 0,4,8 and 12weeks afte ingestion

Countries

Japan

Contacts

Public ContactChiyo Yoshizane

Hayashibara CO., LTD. R&D Division, Development Unit

chiyo.yoshizane@hb.nagase.co.jp086-276-3141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026